Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE versus NORGESTIMATE ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE versus NORGESTIMATE ETHINYL ESTRADIOL.
NORETHINDRONE vs NORGESTIMATE; ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Category D/X
Category D/X
Progestin
Progestin + Estrogen